[96a5a0]: / output / allTrials / logical / NCT00769548_logical.json

Download this file

724 lines (724 with data), 38.2 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
{
"info": {
"nct_id": "NCT00769548",
"official_title": "A PHASE III TRIAL COMPARING WHOLE PELVIC IRRADIATION FOLLOWED BY A CONEDOWN BOOST TO BOOST IRRADIATION ONLY AND COMPARING NEOADJUVANT TO ADJUVANT TOTAL ANDROGEN SUPPRESSION (TAS)",
"inclusion_criteria": "Healthy volunteers allowed\nMust be MALE\nMust have maximum age of 120 Years",
"exclusion_criteria": "",
"miscellaneous_criteria": "DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the prostate Any stage with an estimated risk of node involvement at least 15% (and therefore at significant risk for local and/or systemic failure) based on pretreatment PSA and Gleason score (GS), e.g.: GS of 7 and PSA greater than 7.5 ng/mL GS of 6 and PSA greater than 22.5 ng/mL GS of 5 and PSA greater than 37.5 ng/mL PSA greater than 4 and less than 100 ng/mL Highest pretreatment value determined by a monoclonal assay that has a normal range of 0-4 ng/mL PSA measured by polyclonal assay (e.g., Yang) that has a normal range of 0-2.5 ng/mL may need to be divided by a conversion factor of approximately 1.5 GS determination required prior to entry No distant metastases No biopsy proven lymph node involvement Ineligible for protocol RTOG-9408 (clinical stages T2c-T4 with GS of 6 or higher are eligible for this study)\n\nPATIENT CHARACTERISTICS: Age: Any age Performance status: Karnofsky 70-100% Hematopoietic: Not specified Hepatic: Liver function tests no greater than 1.2 times normal Renal: Not specified Other: No major medical or psychiatric illness that would prevent completion of treatment or interfere with follow-up No second malignancy within 5 years except superficial nonmelanomatous skin cancer\n\nPRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: At least 90 days since testosterone At least 60 days since finasteride Radiotherapy: No prior radiotherapy Surgery: No more than 60 days since surgical staging No radical surgery or cryosurgery"
},
"inclusion_lines": [
{
"identified_line": {
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
}
},
{
"identified_line": {
"line": "Must be MALE",
"criterions": [
{
"exact_snippets": "MALE",
"criterion": "gender",
"requirement": {
"requirement_type": "expected_value",
"expected_value": "male"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "MALE",
"criterion": "gender",
"requirement": {
"requirement_type": "expected_value",
"expected_value": "male"
}
}
]
}
},
{
"identified_line": {
"line": "Must have maximum age of 120 Years",
"criterions": [
{
"exact_snippets": "maximum age of 120 Years",
"criterion": "age",
"requirement": {
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 120,
"unit": "Years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "maximum age of 120 Years",
"criterion": "age",
"requirement": {
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 120,
"unit": "Years"
}
}
}
]
}
}
],
"exclusion_lines": [],
"miscellaneous_lines": [
{
"identified_line": {
"line": "DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the prostate Any stage with an estimated risk of node involvement at least 15% (and therefore at significant risk for local and/or systemic failure) based on pretreatment PSA and Gleason score (GS), e.g.: GS of 7 and PSA greater than 7.5 ng/mL GS of 6 and PSA greater than 22.5 ng/mL GS of 5 and PSA greater than 37.5 ng/mL PSA greater than 4 and less than 100 ng/mL Highest pretreatment value determined by a monoclonal assay that has a normal range of 0-4 ng/mL PSA measured by polyclonal assay (e.g., Yang) that has a normal range of 0-2.5 ng/mL may need to be divided by a conversion factor of approximately 1.5 GS determination required prior to entry No distant metastases No biopsy proven lymph node involvement Ineligible for protocol RTOG-9408 (clinical stages T2c-T4 with GS of 6 or higher are eligible for this study)",
"criterions": [
{
"exact_snippets": "Histologically confirmed adenocarcinoma of the prostate",
"criterion": "adenocarcinoma of the prostate",
"requirement": {
"requirement_type": "confirmation",
"expected_value": "histologically confirmed"
}
},
{
"exact_snippets": "Any stage with an estimated risk of node involvement at least 15%",
"criterion": "risk of node involvement",
"requirement": {
"requirement_type": "estimated risk",
"expected_value": {
"operator": ">=",
"value": 15,
"unit": "%"
}
}
},
{
"exact_snippets": "Any stage with an estimated risk of node involvement at least 15%",
"criterion": "risk of node involvement",
"requirement": {
"requirement_type": "stage",
"expected_value": "any"
}
},
{
"exact_snippets": "pretreatment PSA and Gleason score (GS)",
"criterion": "pretreatment PSA and Gleason score",
"requirement": {
"requirement_type": "GS",
"expected_value": [
">=7 and PSA > 7.5 ng/mL",
">=6 and PSA > 22.5 ng/mL",
">=5 and PSA > 37.5 ng/mL"
]
}
},
{
"exact_snippets": "PSA greater than 4 and less than 100 ng/mL",
"criterion": "PSA level",
"requirement": {
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">",
"value": 4,
"unit": "ng/mL"
},
{
"operator": "<",
"value": 100,
"unit": "ng/mL"
}
]
}
}
},
{
"exact_snippets": "Highest pretreatment value determined by a monoclonal assay that has a normal range of 0-4 ng/mL",
"criterion": "PSA pretreatment value",
"requirement": {
"requirement_type": "determination method",
"expected_value": "monoclonal assay"
}
},
{
"exact_snippets": "Highest pretreatment value determined by a monoclonal assay that has a normal range of 0-4 ng/mL",
"criterion": "PSA pretreatment value",
"requirement": {
"requirement_type": "normal range",
"expected_value": "0-4 ng/mL"
}
},
{
"exact_snippets": "PSA measured by polyclonal assay (e.g., Yang) that has a normal range of 0-2.5 ng/mL",
"criterion": "PSA measurement method",
"requirement": {
"requirement_type": "method",
"expected_value": "polyclonal assay"
}
},
{
"exact_snippets": "PSA measured by polyclonal assay (e.g., Yang) that has a normal range of 0-2.5 ng/mL",
"criterion": "PSA measurement method",
"requirement": {
"requirement_type": "normal range",
"expected_value": "0-2.5 ng/mL"
}
},
{
"exact_snippets": "GS determination required prior to entry",
"criterion": "GS determination",
"requirement": {
"requirement_type": "timing",
"expected_value": "required prior to entry"
}
},
{
"exact_snippets": "No distant metastases",
"criterion": "distant metastases",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "No biopsy proven lymph node involvement",
"criterion": "biopsy proven lymph node involvement",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "Ineligible for protocol RTOG-9408",
"criterion": "eligibility for protocol RTOG-9408",
"requirement": {
"requirement_type": "eligibility",
"expected_value": false
}
},
{
"exact_snippets": "clinical stages T2c-T4 with GS of 6 or higher are eligible for this study",
"criterion": "clinical stage and GS",
"requirement": {
"requirement_type": "stage",
"expected_value": "T2c-T4"
}
},
{
"exact_snippets": "clinical stages T2c-T4 with GS of 6 or higher are eligible for this study",
"criterion": "clinical stage and GS",
"requirement": {
"requirement_type": "GS",
"expected_value": ">=6"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Histologically confirmed adenocarcinoma of the prostate",
"criterion": "adenocarcinoma of the prostate",
"requirement": {
"requirement_type": "confirmation",
"expected_value": "histologically confirmed"
}
},
{
"exact_snippets": "Any stage with an estimated risk of node involvement at least 15%",
"criterion": "risk of node involvement",
"requirement": {
"requirement_type": "estimated risk",
"expected_value": {
"operator": ">=",
"value": 15,
"unit": "%"
}
}
},
{
"exact_snippets": "Any stage with an estimated risk of node involvement at least 15%",
"criterion": "risk of node involvement",
"requirement": {
"requirement_type": "stage",
"expected_value": "any"
}
},
{
"or_criteria": [
{
"exact_snippets": "pretreatment PSA and Gleason score (GS)",
"criterion": "pretreatment PSA and Gleason score",
"requirement": {
"requirement_type": "GS",
"expected_value": [
">=7 and PSA > 7.5 ng/mL",
">=6 and PSA > 22.5 ng/mL",
">=5 and PSA > 37.5 ng/mL"
]
}
},
{
"and_criteria": [
{
"exact_snippets": "PSA greater than 4 and less than 100 ng/mL",
"criterion": "PSA level",
"requirement": {
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">",
"value": 4,
"unit": "ng/mL"
},
{
"operator": "<",
"value": 100,
"unit": "ng/mL"
}
]
}
}
},
{
"exact_snippets": "Highest pretreatment value determined by a monoclonal assay that has a normal range of 0-4 ng/mL",
"criterion": "PSA pretreatment value",
"requirement": {
"requirement_type": "determination method",
"expected_value": "monoclonal assay"
}
},
{
"exact_snippets": "Highest pretreatment value determined by a monoclonal assay that has a normal range of 0-4 ng/mL",
"criterion": "PSA pretreatment value",
"requirement": {
"requirement_type": "normal range",
"expected_value": "0-4 ng/mL"
}
},
{
"exact_snippets": "PSA measured by polyclonal assay (e.g., Yang) that has a normal range of 0-2.5 ng/mL",
"criterion": "PSA measurement method",
"requirement": {
"requirement_type": "method",
"expected_value": "polyclonal assay"
}
},
{
"exact_snippets": "PSA measured by polyclonal assay (e.g., Yang) that has a normal range of 0-2.5 ng/mL",
"criterion": "PSA measurement method",
"requirement": {
"requirement_type": "normal range",
"expected_value": "0-2.5 ng/mL"
}
}
]
}
]
},
{
"exact_snippets": "GS determination required prior to entry",
"criterion": "GS determination",
"requirement": {
"requirement_type": "timing",
"expected_value": "required prior to entry"
}
},
{
"exact_snippets": "No distant metastases",
"criterion": "distant metastases",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "No biopsy proven lymph node involvement",
"criterion": "biopsy proven lymph node involvement",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "Ineligible for protocol RTOG-9408",
"criterion": "eligibility for protocol RTOG-9408",
"requirement": {
"requirement_type": "eligibility",
"expected_value": false
}
}
]
},
{
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "clinical stages T2c-T4 with GS of 6 or higher are eligible for this study",
"criterion": "clinical stage and GS",
"requirement": {
"requirement_type": "stage",
"expected_value": "T2c-T4"
}
},
{
"exact_snippets": "clinical stages T2c-T4 with GS of 6 or higher are eligible for this study",
"criterion": "clinical stage and GS",
"requirement": {
"requirement_type": "GS",
"expected_value": ">=6"
}
}
]
}
]
}
]
}
},
{
"identified_line": {
"line": "PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: At least 90 days since testosterone At least 60 days since finasteride Radiotherapy: No prior radiotherapy Surgery: No more than 60 days since surgical staging No radical surgery or cryosurgery",
"criterions": [
{
"exact_snippets": "No prior chemotherapy",
"criterion": "prior chemotherapy",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "At least 90 days since testosterone",
"criterion": "time since testosterone",
"requirement": {
"requirement_type": "time since",
"expected_value": {
"operator": ">=",
"value": 90,
"unit": "days"
}
}
},
{
"exact_snippets": "At least 60 days since finasteride",
"criterion": "time since finasteride",
"requirement": {
"requirement_type": "time since",
"expected_value": {
"operator": ">=",
"value": 60,
"unit": "days"
}
}
},
{
"exact_snippets": "No prior radiotherapy",
"criterion": "prior radiotherapy",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "No more than 60 days since surgical staging",
"criterion": "time since surgical staging",
"requirement": {
"requirement_type": "time since",
"expected_value": {
"operator": "<=",
"value": 60,
"unit": "days"
}
}
},
{
"exact_snippets": "No radical surgery or cryosurgery",
"criterion": "radical surgery or cryosurgery",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "No prior chemotherapy",
"criterion": "prior chemotherapy",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "No prior radiotherapy",
"criterion": "prior radiotherapy",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
}
]
},
{
"exact_snippets": "At least 90 days since testosterone",
"criterion": "time since testosterone",
"requirement": {
"requirement_type": "time since",
"expected_value": {
"operator": ">=",
"value": 90,
"unit": "days"
}
}
},
{
"exact_snippets": "At least 60 days since finasteride",
"criterion": "time since finasteride",
"requirement": {
"requirement_type": "time since",
"expected_value": {
"operator": ">=",
"value": 60,
"unit": "days"
}
}
},
{
"exact_snippets": "No more than 60 days since surgical staging",
"criterion": "time since surgical staging",
"requirement": {
"requirement_type": "time since",
"expected_value": {
"operator": "<=",
"value": 60,
"unit": "days"
}
}
},
{
"exact_snippets": "No radical surgery or cryosurgery",
"criterion": "radical surgery or cryosurgery",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
}
]
}
}
],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": [
{
"identified_line": {
"line": "PATIENT CHARACTERISTICS: Age: Any age Performance status: Karnofsky 70-100% Hematopoietic: Not specified Hepatic: Liver function tests no greater than 1.2 times normal Renal: Not specified Other: No major medical or psychiatric illness that would prevent completion of treatment or interfere with follow-up No second malignancy within 5 years except superficial nonmelanomatous skin cancer",
"criterions": [
{
"exact_snippets": "Age: Any age",
"criterion": "age",
"requirement": {
"requirement_type": "range",
"expected_value": "any"
}
},
{
"exact_snippets": "Performance status: Karnofsky 70-100%",
"criterion": "performance status",
"requirement": {
"requirement_type": "scale",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 70,
"unit": "%"
},
{
"operator": "<=",
"value": 100,
"unit": "%"
}
]
}
}
},
{
"exact_snippets": "Hematopoietic: Not specified",
"criterion": "hematopoietic",
"requirement": {
"requirement_type": "specification",
"expected_value": "not specified"
}
},
{
"exact_snippets": "Hepatic: Liver function tests no greater than 1.2 times normal",
"criterion": "hepatic function",
"requirement": {
"requirement_type": "liver function tests",
"expected_value": {
"operator": "<=",
"value": 1.2,
"unit": "times normal"
}
}
},
{
"exact_snippets": "Renal: Not specified",
"criterion": "renal function",
"requirement": {
"requirement_type": "specification",
"expected_value": "not specified"
}
},
{
"exact_snippets": "Other: No major medical or psychiatric illness that would prevent completion of treatment or interfere with follow-up",
"criterion": "major medical or psychiatric illness",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "No second malignancy within 5 years except superficial nonmelanomatous skin cancer",
"criterion": "second malignancy within 5 years",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "No second malignancy within 5 years except superficial nonmelanomatous skin cancer",
"criterion": "second malignancy within 5 years",
"requirement": {
"requirement_type": "exception",
"expected_value": "superficial nonmelanomatous skin cancer"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Age: Any age",
"criterion": "age",
"requirement": {
"requirement_type": "range",
"expected_value": "any"
}
},
{
"exact_snippets": "Performance status: Karnofsky 70-100%",
"criterion": "performance status",
"requirement": {
"requirement_type": "scale",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 70,
"unit": "%"
},
{
"operator": "<=",
"value": 100,
"unit": "%"
}
]
}
}
}
]
},
{
"exact_snippets": "Hepatic: Liver function tests no greater than 1.2 times normal",
"criterion": "hepatic function",
"requirement": {
"requirement_type": "liver function tests",
"expected_value": {
"operator": "<=",
"value": 1.2,
"unit": "times normal"
}
}
},
{
"not_criteria": {
"exact_snippets": "Other: No major medical or psychiatric illness that would prevent completion of treatment or interfere with follow-up",
"criterion": "major medical or psychiatric illness",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
}
},
{
"not_criteria": {
"and_criteria": [
{
"exact_snippets": "No second malignancy within 5 years except superficial nonmelanomatous skin cancer",
"criterion": "second malignancy within 5 years",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "No second malignancy within 5 years except superficial nonmelanomatous skin cancer",
"criterion": "second malignancy within 5 years",
"requirement": {
"requirement_type": "exception",
"expected_value": "superficial nonmelanomatous skin cancer"
}
}
]
}
}
]
}
}
]
}